Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E184.43 EPS (ttm)3.15 Insider Own0.20% Shs Outstand103.28M Perf Week5.16%
Market Cap60.00B Forward P/E42.52 EPS next Y13.66 Insider Trans-41.06% Shs Float76.01M Perf Month13.41%
Income358.70M PEG8.65 EPS next Q2.77 Inst Own73.00% Short Float5.91% Perf Quarter24.80%
Sales3.06B P/S19.59 EPS this Y-19.40% Inst Trans-0.07% Short Ratio6.09 Perf Half Y41.97%
Book/sh29.07 P/B19.98 EPS next Y22.55% ROA9.40% Target Price535.04 Perf Year78.51%
Cash/sh7.19 P/C80.84 EPS next 5Y21.32% ROE13.70% 52W Range314.00 - 569.91 Perf YTD41.61%
Dividend- P/FCF272.97 EPS past 5Y41.20% ROI12.50% 52W High1.94% Beta0.89
Dividend %- Quick Ratio4.10 Sales past 5Y49.40% Gross Margin92.00% 52W Low85.01% ATR15.86
Employees2925 Current Ratio4.30 Sales Q/Q39.00% Oper. Margin30.60% RSI (14)69.50 Volatility3.13% 2.42%
OptionableYes Debt/Eq0.16 EPS Q/Q8.20% Profit Margin11.70% Rel Volume2.70 Prev Close554.27
ShortableYes LT Debt/Eq0.16 EarningsAug 04 BMO Payout0.00% Avg Volume737.84K Price580.94
Recom2.10 SMA207.01% SMA5010.54% SMA20028.59% Volume1,930,600 Change4.81%
Aug-04-15Reiterated Brean Capital Buy $525 → $659
Aug-03-15Reiterated Leerink Partners Outperform $559 → $630
Jul-27-15Reiterated RBC Capital Mkts Outperform $560 → $570
Jul-22-15Initiated Northland Capital Market Perform $560
Jul-20-15Reiterated RBC Capital Mkts Outperform $550 → $560
Jul-13-15Reiterated Deutsche Bank Buy $455 → $650
Jun-15-15Reiterated RBC Capital Mkts Outperform $543 → $550
Jun-10-15Reiterated Chardan Capital Markets Buy $560 → $565
May-20-15Reiterated Canaccord Genuity Buy $525 → $600
May-20-15Reiterated Argus Buy $500 → $560
May-19-15Reiterated Brean Capital Buy $507 → $525
May-15-15Reiterated JP Morgan Neutral $427 → $450
May-08-15Reiterated UBS Neutral $412 → $500
May-08-15Reiterated Canaccord Genuity Buy $460 → $525
May-08-15Reiterated Brean Capital Buy $450 → $507
May-07-15Reiterated ROTH Capital Neutral $461 → $490
May-06-15Reiterated Leerink Partners Outperform $527 → $559
Apr-29-15Reiterated RBC Capital Mkts Outperform $490 → $533
Apr-24-15Reiterated Leerink Partners Outperform $445 → $527
Mar-27-15Reiterated Argus Buy $450 → $500
Aug-05-15 12:33AM  Bird in Regenerons Hand Is Enough at The Wall Street Journal
Aug-04-15 06:25PM  Stock Market Today - 08/04/15
06:12PM  Cramer: Why Apple is not for the squeamish at CNBC
06:00PM  Regeneron Surges On Strong Outlook, As Does Abiomed
04:24PM  Stocks Bleed More Red; Apple Weak Again, Suppliers Hit Too at Investor's Business Daily
03:25PM  Edited Transcript of REGN earnings conference call or presentation 4-Aug-15 12:30pm GMT
03:03PM  Evercore Breaks Down Regeneron's Q2 Report
02:14PM  Regeneron Tops 3 Med Stocks Moving Big On Earnings
01:36PM  Bird in Regeneron's Hand Is Enough at The Wall Street Journal
01:25PM  Technology, Semiconductor ETFs Slump On Apple's Plunge at Investor's Business Daily
01:05PM  Regeneron Pops On Upbeat Q2 at Barrons.com
01:03PM  Regeneron's Knock-out Quarter Could Be Just The Beginning at Motley Fool
12:39PM  Regeneron Raises Sales Forecast on Demand for Top Drug Eylea at Bloomberg
12:37PM  Regeneron, Abiomed Surge On Strong Quarters, Guidance at Investor's Business Daily
10:29AM  Cramer -- Dont Bet Against R.R. Donnelley & Sons or Regeneron at TheStreet
10:00AM  Regeneron Beats on Q2 Earnings, Eylea 2015 View Upped - Analyst Blog
09:23AM  Cramer's Mad Dash: RRD's 3-way split
09:19AM  Morning Movers: Futures Edge Lower, Coach, Regeneron Soar at Barrons.com
07:54AM  Early movers: AET, TIME, REGN, BABA, ADM & more at CNBC
07:38AM  Regeneron (REGN) Beats on Q2 Earnings, Updates 2015 View - Tale of the Tape
07:16AM  Regeneron Pharmaceuticals Profit Doubles at The Wall Street Journal
07:11AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financ
07:07AM  Q2 2015 Regeneron Pharmaceuticals Inc Earnings Release - Before Market Open
06:45AM  Regeneron tops Street 2Q forecasts
06:39AM  Drugmaker Regeneron's revenue jumps on Eylea sales
06:30AM  Regeneron Reports Second Quarter 2015 Financial and Operating Results PR Newswire
Aug-03-15 07:03PM  Markets find new sources of angst at CNBC
04:59PM  5 Biotechs With Catalysts Coming This Week
03:18PM  What to Watch in the Day Ahead - Tuesday, August 4 Reuters
02:18PM  Health, Consumer ETFs Holding IBD 50 Stocks Set To Report at Investor's Business Daily
01:05PM  5 Top Medical Stocks Reporting Earnings This Week at Investor's Business Daily
11:40AM  Regeneron Still Has Legs: Leerink Targets $630 a Share at Barrons.com
Aug-01-15 08:02AM  IBD 50: 10 Top Stocks Reporting Earnings This Week at Investor's Business Daily
Jul-31-15 06:59PM  Cramer Remix: If China falls, buy this stock at CNBC
06:09PM  Cramer game plan: Prep for sharp selloff next week at CNBC
06:00PM  Cramer: Keep one eye on earnings & the other on the big p...
04:24PM  Express Scripts excludes 20 more drugs from 2016 coverage Reuters
03:10PM  Will Regeneron (REGN) Earnings Surprise on Eylea Sales? - Analyst Blog
12:06PM  Sanofi Tops Q2 Earnings, Revenues Grow Y/Y, Maintains View - Analyst Blog
11:02AM  This is Why Amgen is Soaring at Barrons.com
06:20AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Jul-30-15 12:13PM  10 Stocks Making Warren Buffett Richer in 2015 at TheStreet
09:30AM  The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases
Jul-29-15 06:26PM  Express Scripts says costly new cholesterol drugs could 'wreak havoc' Reuters
03:45PM  Sanofi & Regeneron Enter Immuno-Oncology Collaboration - Analyst Blog
11:48AM  Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog
11:27AM  Sanofi-Regeneron: Third Time's the Charm? at Barrons.com
11:02AM  Four Reasons Gilead Can Head Higher at Barrons.com
Jul-28-15 08:07PM  5 Hot Drug Stocks Top IBD's Big Cap Leaders Screen at Investor's Business Daily
05:32PM  Pfizer, Merck Beat Q2 Views; Sanofi Makes PD-1 Deal at Investor's Business Daily
03:24PM  Bah Baidu! Internet ETFs Eye Facebook, Twitter Results at Investor's Business Daily
01:57PM  Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders?
11:58AM  Esperion Therapeutics: Four Reasons Bear Case Hard to Debunk at Barrons.com
11:08AM  Regeneron's George Yancopoulos Becomes Pharma's First Billionaire R&D Chief at Forbes
10:23AM  Struggling Sanofi Sends Cancer SOS to Regeneron and Another Vanity Biotech IPO Launches at TheStreet
09:30AM  The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
08:59AM  July 28 Premarket Briefing: 10 Things You Should Know
02:42AM  Sanofi links with Regeneron in $2.2 bln cancer drug push
01:00AM  Sanofi Joins Regeneron in $2.2 Billion Pact for Cancer Therapies at Bloomberg
01:00AM  Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration PR Newswire
Jul-27-15 02:56PM  Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval at Motley Fool
12:43PM  Why Regeneron's Approval is Bad News For Esperion Therapeutics at Barrons.com
11:53AM  Have Analysts Fully Priced in Praluent to Regeneron?
08:45AM  Praluent priced on value: Regeneron CEO
06:02AM  New heart drugs come in more expensive than expected Reuters
Jul-24-15 05:24PM  Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK at Investor's Business Daily
05:24PM  Regeneron Cholesterol Fighter Wins FDA OK, With Conditions
04:41PM  Trending Now: REGN
03:53PM  Sanofi and Regeneron Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients PR Newswire
03:30PM  Sanofi and Regeneron Conference Call to discuss on The PRALUENT
03:23PM  The FDA Approves A Potent And Pricey Cholesterol-Lowering Shot at Forbes
03:19PM  Regeneron: Here's Your Next $12,000 Wonder Drug at Barrons.com
03:17PM  Regeneron and Sanofi Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients PR Newswire
02:46PM  FDA Approves Cholesterol Drug From Regeneron, Sanofi at The Wall Street Journal
02:22PM  FDA approves cholesterol drug
01:28PM  Docs are Excited About Prescribing Those New Cholesterol Drugs: Survey at The Wall Street Journal
09:24AM  Cramer's Mad Dash: Biogen's biotech blues
07:15AM  Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia PR Newswire
07:07AM  Sanofi's big new cholesterol drug wins European green light Reuters
Jul-23-15 05:30PM  Cholesterol drug wars
01:44PM  FDA Oks Pricey New Cholesterol Drug For Certain Patients at Fox Business
Jul-22-15 05:32AM  Coverage initiated on Regeneron Pharms by Northland Capital
03:37AM  Amgen and Sanofi to battle for cholesterol-busting crown at Financial Times
Jul-21-15 07:53AM  Amgen wins first approval for new class of cholesterol drugs Reuters
12:09AM  Rising U.S. Drug Prices Are Focus of Research Grant at The Wall Street Journal
Jul-20-15 07:05PM  Rising U.S. Drug Prices Are Focus of Research Grant at The Wall Street Journal
05:40PM  IBM shares tumble after revenue miss at MarketWatch
08:50AM  4 Large Cap Biotech Stocks to Buy Before Earnings at 24/7 Wall St.
Jul-16-15 04:30PM  Ohr Pharmaceutical Jumps on Positive Eye Drug Study Data - Analyst Blog
Jul-15-15 12:31PM  More Upside Coming for a Popular Biotech ETF
Jul-14-15 04:50PM  Anacor Hits 52-Week High on Positive Atopic Dermatitis Data - Analyst Blog
Jul-13-15 04:24PM  It was another strong showing for equity averages...
02:40PM  Regeneron: Six Reasons for $650 at Barrons.com
12:21PM  Anacor, Regeneron Up On Promising Rash Treatments at Investor's Business Daily
Jul-11-15 02:02PM  Why July Will Be an Exciting Month for Regeneron Pharmaceuticals at Motley Fool
Jul-09-15 03:20PM  What to Buy in Biotech at Barrons.com
02:24PM  Regeneron 'Sell' Rating Is Right Call for This Biotech at Barrons.com
11:30AM  Regeneron and Sanofi Report Positive Data on Praluent - Analyst Blog
11:12AM  Regeneron, Amgen Downgraded As Biotech Seen Slowing at Investor's Business Daily
08:55AM  UBS 'Looking Elsewhere,' Says To Sell Regeneron
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration (AMD) and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes comprising familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. The company's trap-based clinical product candidates comprise EYLEA for the treatment of AMD and diabetic macular edema; and ZALTRAP for oncology. Its antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN727 for low-density lipoprotein cholesterol reduction and for the prevention of cardiovascular events; REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN668 for atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis; REGN2222 for respiratory syncytial virus; REGN1033 for skeletal muscle disorders; and REGN2176-3 and REGN910-3 antibodies for use in ophthalmology. The company is also developing REGN1908-1909, REGN1154, REGN1500, and REGN1193 antibody product candidates; REGN1400, REGN1979, and REGN2810 for oncology; and REGN475 for the treatment of pain. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA, as well as with Avalanche Biotechnologies, Inc. to discover, develop, and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDSTEIN JOSEPH LDirectorJul 15Sale550.002,0001,100,00016,000Jul 15 04:09 PM
GOLDSTEIN JOSEPH LDirectorJun 22Sale526.852,0001,053,70018,000Jun 22 05:02 PM
SING GEORGE LDirectorMay 27Option Exercise19.695,00098,450117,772May 29 04:19 PM
SING GEORGE LDirectorMay 27Sale515.005,0002,575,000112,772May 29 04:19 PM
INGRAM ROBERT ALEXANDERDirectorMay 27Sale513.391,379707,9651,500May 27 04:02 PM
INGRAM ROBERT ALEXANDERDirectorMay 22Option Exercise293.536,6671,956,9656,667May 27 04:02 PM
McCorkle Douglas SVP Controller and Asst TreasurMay 22Option Exercise174.0113,4642,342,90217,481May 26 04:31 PM
GOLDSTEIN JOSEPH LDirectorMay 22Sale514.284,0002,057,10020,000May 26 04:30 PM
McCorkle Douglas SVP Controller and Asst TreasurMay 22Sale515.6013,0006,702,8004,481May 26 04:31 PM
BROWN MICHAEL SDirectorMay 15Option Exercise57.115,000285,5505,000May 18 04:50 PM
BROWN MICHAEL SDirectorMay 15Sale495.005,0002,475,0000May 18 04:50 PM
Landry Robert ESVP Finance & CFOApr 08Option Exercise272.7010,0002,727,00015,000Apr 09 04:03 PM
BAKER CHARLES ADirectorMar 25Option Exercise18.615,00093,05014,000Mar 26 04:20 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 25Option Exercise59.203,097183,34215,067Mar 26 04:21 PM
BAKER CHARLES ADirectorMar 25Sale454.965,0002,274,7859,000Mar 26 04:20 PM
Aberman Michael SSVP Strategy Investor RelationMar 24Sale478.994,8432,319,73812,498Mar 25 04:07 PM
Aberman Michael SSVP Strategy Investor RelationMar 18Sale465.003,4421,600,54222,498Mar 19 04:05 PM
Aberman Michael SSVP Strategy Investor RelationMar 17Option Exercise24.0011,398273,55229,998Mar 19 04:05 PM
Terifay Robert JSVP CommercialMar 17Sale451.0110,9934,957,90720,029Mar 18 06:03 PM
Terifay Robert JSVP CommercialMar 16Option Exercise30.6324,375746,60644,404Mar 18 06:03 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 16Option Exercise59.2020,2811,200,63528,311Mar 17 04:57 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 16Sale450.0018,3118,239,95010,000Mar 17 04:57 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 27Sale416.243,0001,248,7204,481Feb 27 04:31 PM
Tessier-Lavigne MarcDirectorFeb 26Option Exercise50.913,000152,7304,187Feb 27 04:32 PM
Tessier-Lavigne MarcDirectorFeb 26Sale421.953,0001,265,8641,187Feb 27 04:32 PM
Aberman Michael SSVP Strategy Investor RelationFeb 24Sale418.483,3741,411,95218,600Feb 25 04:02 PM
Terifay Robert JSVP CommercialFeb 24Sale423.6711,1734,733,66520,029Feb 25 04:01 PM
Aberman Michael SSVP Strategy Investor RelationFeb 23Option Exercise30.637,500229,72526,100Feb 25 04:02 PM
Terifay Robert JSVP CommercialFeb 23Option Exercise30.6324,375746,60644,404Feb 25 04:01 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 23Sale427.829,4314,034,75418,705Feb 24 05:08 PM
RYAN ARTHUR FDirectorFeb 20Option Exercise125.7929,2503,679,49876,750Feb 23 04:06 PM
BROWN MICHAEL SDirectorFeb 20Option Exercise57.111,00057,1101,000Feb 23 04:07 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Option Exercise177.825,000889,1009,000Feb 20 04:44 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 20Option Exercise21.2520,000425,00038,705Feb 24 05:08 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Sale423.655,0002,118,2624,000Feb 20 04:44 PM
RYAN ARTHUR FDirectorFeb 20Sale423.0129,25012,372,90847,500Feb 23 04:06 PM
BROWN MICHAEL SDirectorFeb 20Sale422.721,000422,7200Feb 23 04:07 PM
Aberman Michael SSVP Strategy Investor RelationFeb 17Sale404.463,6921,493,26618,600Feb 18 04:40 PM
Aberman Michael SSVP Strategy Investor RelationFeb 13Option Exercise24.007,500180,00026,100Feb 18 04:40 PM
SCHLEIFER LEONARD SPresident & CEOJan 02Sale410.581,500615,8670Jan 05 04:56 PM
Powchik PeterSVP Clinical Development & RegJan 02Sale414.0810,8224,481,21410,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 31Option Exercise52.0325,0001,300,75035,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 19Option Exercise30.633,26499,97610,711Dec 22 12:09 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 18Option Exercise30.633,26499,97618,705Dec 19 02:11 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 17Option Exercise30.632,80085,7647,481Dec 18 04:22 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrDec 16Option Exercise30.633,26499,97664,436Dec 18 04:25 PM
STAHL NEILSVP Research and Development SDec 16Option Exercise30.633,26499,9766,541Dec 18 04:25 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise30.633,26499,976503,264Dec 18 04:23 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise49.076,818334,56010,556Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Sale410.006,8182,795,3804,681Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Option Exercise30.631,66851,0916,049Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Sale410.761,668685,1444,681Dec 17 04:51 PM
POON CHRISTINE ADirectorNov 25Buy410.00400164,000655Nov 26 01:28 PM
GILMAN ALFRED GDirectorNov 24Option Exercise35.9640,0001,438,55040,000Nov 25 04:16 PM
GILMAN ALFRED GDirectorNov 24Sale408.4440,00016,337,5850Nov 25 04:16 PM
STAHL NEILSVP Research and Development SNov 24Sale409.782,200901,5233,277Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 21Sale415.163,1071,289,9025,477Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 18Option Exercise115.2916,7571,931,91530,284Nov 20 04:14 PM
Terifay Robert JSVP CommercialNov 18Sale405.7922,3629,074,20020,029Nov 19 04:41 PM
Terifay Robert JSVP CommercialNov 17Option Exercise21.2548,7501,035,93868,779Nov 19 04:41 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 13Sale399.348,5753,424,33615,441Nov 14 04:32 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 12Option Exercise21.2518,700397,37534,141Nov 14 04:32 PM
GOLDSTEIN JOSEPH LDirectorNov 12Option Exercise177.825,000889,1009,000Nov 12 05:15 PM
GOLDSTEIN JOSEPH LDirectorNov 12Sale398.315,0001,991,5504,000Nov 12 05:15 PM
SCHLEIFER LEONARD SPresident & CEONov 12Sale400.3242,32416,943,28542,087Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEONov 11Sale400.003,4931,397,20084,411Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEOOct 31Sale400.113,4531,381,58087,904Nov 04 04:06 PM
SCHLEIFER LEONARD SPresident & CEOOct 28Sale404.0169,11227,921,80691,357Oct 29 04:27 PM
SCHLEIFER LEONARD SPresident & CEOOct 27Option Exercise19.40256,8084,982,219292,893Oct 29 04:27 PM
BROWN MICHAEL SDirectorOct 24Option Exercise57.115,000285,5505,000Oct 24 04:07 PM
BROWN MICHAEL SDirectorOct 24Sale399.005,0001,995,0000Oct 24 04:07 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 24Sale400.7026,78810,734,01863,102Oct 27 04:17 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 23Option Exercise30.6360,0001,837,800123,102Oct 27 04:17 PM
VAGELOS P ROYChairman of the BoardSep 10Sale350.0710,3263,614,82392,947Sep 10 04:00 PM
VAGELOS P ROYChairman of the BoardSep 08Sale351.002702103,273Sep 10 04:00 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriAug 27Option Exercise314.315,7201,797,853505,720Aug 29 03:29 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 27Option Exercise21.561,68136,2474,681Aug 28 02:39 PM
Tessier-Lavigne MarcDirectorAug 27Option Exercise50.913,000152,7304,187Aug 27 05:02 PM
Tessier-Lavigne MarcDirectorAug 27Sale352.203,0001,056,6001,187Aug 27 05:02 PM
GOLDSTEIN JOSEPH LDirectorAug 27Sale350.312,000700,6204,000Aug 27 05:01 PM
Tessier-Lavigne MarcDirectorAug 26Option Exercise50.911,38770,6121,387Aug 27 05:02 PM
Aberman Michael SVP Strategy and Investor RelatAug 22Option Exercise24.003,00072,00018,600Aug 26 09:45 AM
Aberman Michael SVP Strategy and Investor RelatAug 19Sale350.003,6111,263,85015,600Aug 19 04:16 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Option Exercise52.035,875305,6768,875Aug 18 04:04 PM
Aberman Michael SVP Strategy and Investor RelatAug 18Option Exercise52.038,750455,26324,350Aug 19 04:16 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Sale353.005,8752,073,8753,000Aug 18 04:04 PM
BROWN MICHAEL SDirectorAug 15Option Exercise33.423,000100,2603,000Aug 18 04:02 PM
BROWN MICHAEL SDirectorAug 15Sale349.203,0001,047,6000Aug 18 04:02 PM
GOLDSTEIN JOSEPH LDirectorAug 14Sale347.652,000695,3006,000Aug 14 04:14 PM
VAGELOS P ROYChairman of the BoardAug 13Sale340.018,0282,729,600248,540Aug 14 04:15 PM
STAHL NEILSVP Research and Development SAug 11Sale339.9611,6463,959,20413,527Aug 11 04:04 PM
VAGELOS P ROYChairman of the BoardAug 11Sale340.059,3723,186,967256,568Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 08Sale340.642,100715,34025,173Aug 08 04:49 PM
VAGELOS P ROYChairman of the BoardAug 08Sale340.332,600884,858265,940Aug 11 05:25 PM
VAGELOS P ROYChairman of the BoardAug 07Option Exercise9.49270,3522,565,640411,191Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 07Sale340.49741252,30427,273Aug 08 04:49 PM
STAHL NEILSVP Research and Development SAug 06Option Exercise21.2535,000743,75048,527Aug 08 04:49 PM
GOLDSTEIN JOSEPH LDirectorAug 06Sale331.202,000662,4008,000Aug 06 04:11 PM